BUZZ - JPMorgan upgrades Biogen rating to "Overweight", stock price rises
路透社2026/10/12 09:21October 12 - ** The share price of pharmaceutical company Biogen (BIIB.O) rose nearly 2% in pre-market trading to $230.35
** JPMorgan upgraded the stock from “Neutral” to “Overweight”; the price target was raised from $210 to $300, representing approximately 33% upside from last Friday’s closing price
** The brokerage believes that several key catalysts will emerge in 2027, including felzartamab for antibody-mediated rejection (AMR) in organ transplantation, with a potential market size in this field exceeding $2 billion
** “We believe that, as the company is no longer just a Leqembi single-story, BIIB will become one of the most attractive investment stocks in 2027.” (This drug is used to treat Alzheimer’s disease)
** On average, 38 analysts rate the stock as a “Buy”; the median price target is $242 — data compiled by LSEG
** As of the previous trading day’s close, the stock had gained 28.25% year-to-date
(To facilitate non-English-speaking users, Reuters provides automated translation of its reports into several other languages. As automated translations may be inaccurate or lack the required context, Reuters does not guarantee the accuracy of the automated translation, which is provided for readers’ convenience only. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Inflation surpasses expectations, impacting small-cap stocks; Russell 2000 drops nearly 2%, confirming a technical correction
On Wednesday, approximately four-fifths of the constituents in the Russell 2000 Index recorded declines. Since its peak in August, the index has dropped by 11%, falling below its 200-day moving average and entering a technical correction for the first time since March this year. Analysis indicates that with the US CPI rising more than expected and the probability of rate hikes increasing, small-cap, consumer, and transportation stocks are facing "sustained and long-term resistance."
Inflation and interest rates hit simultaneously, Russell 2000 plunges 11% from August high, marking its first technical correction since March
With both inflation and interest rates rising, the Russell 2000 has fallen 11% from its August peak, breaking below its 200-day moving average and recording its first technical correction since March.
Tesla (TSLA.US) and SpaceX (SPCX.US) merger countdown? Barclays: Announcement possible this year, obstacle lies in shareholder voting
Barclays analysts stated that a potential merger between Elon Musk's Tesla and SpaceX could be announced before the electric vehicle manufacturer's annual shareholder meeting.
Crypto prices
More
